Idiopathic pulmonary fibrosis

[1]  J. Qian,et al.  miR-29 is a major regulator of genes associated with pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.

[2]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[3]  Ivana V. Yang,et al.  A common MUC5B promoter polymorphism and pulmonary fibrosis. , 2011, The New England journal of medicine.

[4]  I. Noth,et al.  A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[5]  P. Wolters,et al.  Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[6]  M. Gershwin,et al.  Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review , 2011, Clinical reviews in allergy & immunology.

[7]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[8]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[9]  J. Derisi,et al.  At a Glance Commentary , 2022 .

[10]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[11]  P. D. de Jong,et al.  Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. , 2010, American journal of respiratory and critical care medicine.

[12]  H. Hoogsteden,et al.  Serum biomarkers in idiopathic pulmonary fibrosis. , 2010, Pulmonary pharmacology & therapeutics.

[13]  M. Selman,et al.  Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis. , 2010, Seminars in respiratory and critical care medicine.

[14]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[15]  Zhen W. Zhuang,et al.  Tissue-Engineered Lungs for in Vivo Implantation , 2010, Science.

[16]  Oliver Eickelberg,et al.  Inhibition and role of let-7d in idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[17]  S. Nathan,et al.  Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. , 2010, Respiratory medicine.

[18]  Jong-Min Song,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome , 2010, European Respiratory Journal.

[19]  A. Nicholson,et al.  Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[20]  Christopher M Waters,et al.  Epithelial repair mechanisms in the lung. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[21]  D. Brazil,et al.  Extracellular BMP-antagonist regulation in development and disease: tied up in knots. , 2010, Trends in cell biology.

[22]  S. Harari,et al.  IPF: new insight on pathogenesis and treatment , 2010, Allergy.

[23]  N. Kaminski,et al.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.

[24]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.

[25]  H. Collard,et al.  Does chronic microaspiration cause idiopathic pulmonary fibrosis? , 2010, The American journal of medicine.

[26]  J. Kere,et al.  ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  E. Wang,et al.  MicroRNA group disorganization in aging , 2010, Experimental Gerontology.

[28]  D. Schroeder,et al.  Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. , 2010, American journal of respiratory and critical care medicine.

[29]  D. Calame,et al.  Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  E. White,et al.  Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[31]  N. Kaminski,et al.  CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis , 2010, PloS one.

[32]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[33]  W. Parks,et al.  Role of matrix metalloproteinases in epithelial migration , 2009, Journal of cellular biochemistry.

[34]  Y. Castier,et al.  Survival After Bilateral Versus Single-Lung Transplantation for Idiopathic Pulmonary Fibrosis , 2009, Annals of Internal Medicine.

[35]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[36]  M. Burdick,et al.  The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis , 2009, Journal of leukocyte biology.

[37]  M. Rojas,et al.  Twist: A Regulator of Epithelial-Mesenchymal Transition in Lung Fibrosis , 2009, PloS one.

[38]  W. Seeger,et al.  SNAI transcription factors mediate epithelial–mesenchymal transition in lung fibrosis , 2009, Thorax.

[39]  E. Neilson,et al.  Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. , 2009, American journal of respiratory and critical care medicine.

[40]  H. Collard,et al.  Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. , 2009, Chest.

[41]  A. Nicholson,et al.  Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. , 2009, The Journal of clinical investigation.

[42]  P. Sime,et al.  INVITED REVIEW SERIES: PULMONARY FIBROSIS , 2009 .

[43]  M. Armanios.  Syndromes of telomere shortening. , 2009, Annual review of genomics and human genetics.

[44]  B. Christensen,et al.  Aging and Environmental Exposures Alter Tissue-Specific DNA Methylation Dependent upon CpG Island Context , 2009, PLoS genetics.

[45]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[46]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[47]  Jin Woo Song,et al.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[48]  T. Colby,et al.  Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. , 2009, Chest.

[49]  T. Suarez,et al.  Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. , 2009, Chest.

[50]  R. Hubbard,et al.  Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. , 2009, Respiratory medicine.

[51]  U. Eriksson,et al.  Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[52]  D. Hansell,et al.  Lung morphology in the elderly: comparative CT study of subjects over 75 years old versus those under 55 years old. , 2009, Radiology.

[53]  K. Boon,et al.  Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF) , 2009, PloS one.

[54]  W. Seeger,et al.  WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. , 2009, The Journal of clinical investigation.

[55]  B. Housset,et al.  Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[56]  P. O'Byrne,et al.  Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[57]  W. Coward,et al.  Defective Histone Acetylation Is Responsible for the Diminished Expression of Cyclooxygenase 2 in Idiopathic Pulmonary Fibrosis , 2009, Molecular and Cellular Biology.

[58]  N. Kaminski,et al.  WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. , 2009, American journal of respiratory cell and molecular biology.

[59]  David S. Rogers,et al.  Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. , 2009, American Journal of Respiratory Cell and Molecular Biology.

[60]  N. Grishin,et al.  Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. , 2009, American journal of human genetics.

[61]  D. Thickett,et al.  MMP expression and abnormal lung permeability are important determinants of outcome in IPF , 2009, European Respiratory Journal.

[62]  B. Driscoll,et al.  Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[63]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.

[64]  C. Ruppert,et al.  Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[65]  M. Selman,et al.  MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis , 2008, Human Genetics.

[66]  M. B. Gazzana,et al.  Fibrose pulmonar idiopática simultânea a enfisema em pacientes tabagistas , 2008 .

[67]  M. Peppelenbosch,et al.  Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. , 2008, Trends in molecular medicine.

[68]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[69]  O. Larsson,et al.  Fibrotic Myofibroblasts Manifest Genome-Wide Derangements of Translational Control , 2008, PloS one.

[70]  P. Lansdorp,et al.  Short telomeres are a risk factor for idiopathic pulmonary fibrosis , 2008, Proceedings of the National Academy of Sciences.

[71]  K. Preissner,et al.  Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. , 2008, American journal of respiratory cell and molecular biology.

[72]  L. Ortiz,et al.  Stem cells and cell therapies in lung biology and lung diseases. , 2008, Proceedings of the American Thoracic Society.

[73]  R. Nho,et al.  Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis , 2008, The Journal of experimental medicine.

[74]  G. Nuovo,et al.  Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. , 2008, American journal of respiratory cell and molecular biology.

[75]  Peter F. Crossno,et al.  Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[76]  W. Seeger,et al.  Functional Wnt Signaling Is Increased in Idiopathic Pulmonary Fibrosis , 2008, PloS one.

[77]  M. Bando,et al.  Torque teno virus DNA titre elevated in idiopathic pulmonary fibrosis with primary lung cancer , 2008, Respirology.

[78]  N. Kaminski,et al.  A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. , 2008, The American journal of pathology.

[79]  N. Kaminski,et al.  Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs? , 2008, PLoS medicine.

[80]  Hye-Youn Cho,et al.  Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. , 2008, Antioxidants & redox signaling.

[81]  M. Selman,et al.  Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. , 2008, The international journal of biochemistry & cell biology.

[82]  H. Tomioka,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: Role of Chlamydophila pneumoniae infection , 2007, Respirology.

[83]  B. Willis,et al.  TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease , 2007 .

[84]  N. Müller,et al.  Acute Exacerbation of Chronic Interstitial Pneumonia: High-resolution Computed Tomography and Pathologic Findings , 2007, Journal of thoracic imaging.

[85]  Giulio Gabbiani,et al.  The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.

[86]  N. Kaminski,et al.  Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern , 2007, PloS one.

[87]  M. Collazo-Clavell,et al.  Body mass index and mortality in patients with idiopathic pulmonary fibrosis. , 2007, Chest.

[88]  Chao Xing,et al.  Adult-onset pulmonary fibrosis caused by mutations in telomerase , 2007, Proceedings of the National Academy of Sciences.

[89]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[90]  F. Martinez,et al.  The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. , 2007, Chest.

[91]  M. Mishima,et al.  Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. , 2007, Chest.

[92]  R. Strieter,et al.  The role of CXC chemokines in pulmonary fibrosis. , 2007, The Journal of clinical investigation.

[93]  Living-donor lung transplantation for end-stage lung disease , 2007 .

[94]  H. Collard,et al.  Acute exacerbations of idiopathic pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[95]  N. Kaminski,et al.  Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis , 2006, The Journal of experimental medicine.

[96]  T. Tsuji,et al.  Alveolar cell senescence in patients with pulmonary emphysema. , 2006, American journal of respiratory and critical care medicine.

[97]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[98]  D. Sheppard,et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.

[99]  R. Hubbard,et al.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK , 2006, Thorax.

[100]  J. Kere,et al.  ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. , 2006, American journal of human genetics.

[101]  K. Salmenkivi,et al.  Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. , 2006, The American journal of pathology.

[102]  J. Horowitz,et al.  Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.

[103]  M. Selman,et al.  Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. , 2006, Proceedings of the American Thoracic Society.

[104]  D. Roberts,et al.  Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. , 2006, Experimental and molecular pathology.

[105]  S. Nathan,et al.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[106]  M. Selman,et al.  Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis. , 2006, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[107]  Naftali Kaminski,et al.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. , 2006, American journal of respiratory and critical care medicine.

[108]  F. Martinez,et al.  Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). , 2006, American journal of respiratory and critical care medicine.

[109]  E. Rieber,et al.  Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells , 2006, Cell and Tissue Research.

[110]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[111]  Katsutoshi Nakayama,et al.  Anticoagulant therapy for idiopathic pulmonary fibrosis. , 2005, Chest.

[112]  Naftali Kaminski,et al.  Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis , 2005, PLoS medicine.

[113]  T. Oury,et al.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. , 2005, American journal of respiratory and critical care medicine.

[114]  T. Hartman,et al.  Familial idiopathic pulmonary fibrosis: clinical features and outcome. , 2005, Chest.

[115]  R. D. du Bois,et al.  Genetics of fibrosing lung diseases , 2005, European Respiratory Journal.

[116]  J. Horowitz,et al.  Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[117]  A. Nicholson,et al.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. , 2005, The American journal of pathology.

[118]  B. Beghé,et al.  Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema , 2005, Respiratory research.

[119]  L L Schulman,et al.  Correlation of lung surface area to apoptosis and proliferation in human emphysema , 2005, European Respiratory Journal.

[120]  P. Pellikka,et al.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. , 2004, Chest.

[121]  Susan Murray,et al.  Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? , 2004, American journal of respiratory and critical care medicine.

[122]  K. Brown,et al.  Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. , 2004, American journal of respiratory and critical care medicine.

[123]  Takashi Suzuki,et al.  Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. , 2004, American journal of respiratory and critical care medicine.

[124]  D. Malarkey,et al.  Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect. , 2004, Chest.

[125]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[126]  Naftali Kaminski,et al.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[127]  J. Oates,et al.  Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis , 2003, Journal of Clinical Microbiology.

[128]  V. Poletti,et al.  Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .

[129]  Gareth A. Stewart,et al.  Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up‐regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes , 2003, The Journal of pathology.

[130]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[131]  J. Stewart,et al.  A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. , 2002, American journal of respiratory and critical care medicine.

[132]  Jonathan Haines,et al.  Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. , 2002, American journal of respiratory and critical care medicine.

[133]  U. Costabel,et al.  ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias , 2002, European Respiratory Journal.

[134]  Naftali Kaminski,et al.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[135]  T. Laitinen,et al.  Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland , 2002, Thorax.

[136]  Demosthenes Bouros,et al.  Association of malignancy with diseases causing interstitial pulmonary changes. , 2002, Chest.

[137]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[138]  A. Yoshimura,et al.  Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. , 2001, Cancer research.

[139]  R. Silver,et al.  Thrombin Differentiates Normal Lung Fibroblasts to a Myofibroblast Phenotype via the Proteolytically Activated Receptor-1 and a Protein Kinase C-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[140]  Y. Nishiwaki,et al.  p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. , 2001, Human pathology.

[141]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[142]  Y. Sugiyama,et al.  Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer. , 2000, Respiratory medicine.

[143]  M. Selman,et al.  TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? , 2000, American journal of physiology. Lung cellular and molecular physiology.

[144]  M. Gaxiola,et al.  Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. , 2000, Chest.

[145]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[146]  M. Fukayama,et al.  Pulmonary fibrosis and lung carcinoma: A comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma , 1999, Pathology international.

[147]  M. Selman,et al.  Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[148]  M. Müller,et al.  Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. , 1998, Cellular and molecular biology.

[149]  M. Burdick,et al.  Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. , 1995, The Journal of clinical investigation.